Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 29, 2021, Kiniksa Pharmaceuticals, Ltd. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") at which a quorum for the transaction of business was present. Holders of the Company's Class A common shares ("Class A Common Shares") and Class B common shares ("Class B Common Shares") as of the close of business on April 15, 2021 (the "Record Date") were entitled to notice of and to vote at the Annual Meeting. Each Class A Common Share is entitled to one vote per share and each Class B Common Share is entitled to ten votes per share.

The following are the voting results for the proposals considered and voted upon at the Annual Meeting, all of which were described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on April 28, 2021.

Proposal 1 - The election of Felix J. Baker, Tracey L. McCain and Kimberly J. Popovits as Class III Directors to serve until the 2024 Annual Meeting of Shareholders and until their respective successors have been duly elected and qualified.





Nominee                Votes FOR    Votes WITHHELD   Broker Non-Votes

Felix J. Baker 32,782,124 8,450,135 3,111,864 Tracey L. McCain 35,881,809 5,350,450 3,111,864 Kimberly J. Popovits 35,840,708 5,391,551 3,111,864

Proposal 2 - The (a) appointment of PricewaterhouseCoopers LLP as the Company's auditor until the close of the Company's next Annual Meeting of Shareholders, (b) delegation to the Company's Board of Directors, through the Audit Committee of the Board of Directors, of the authority to set the auditor's remuneration for such period, and (c) ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021.





Votes FOR    Votes AGAINST   Votes ABSTAINED   Broker Non-Votes
44,257,066      65,984           21,073               0

Proposal 3 - The approval, on a non-binding, advisory basis, of the compensation of our named executive officers as disclosed in the Company's proxy statement for the Annual Meeting pursuant to the applicable compensation disclosure rules of the Securities and Exchange Commission, including the compensation tables and narrative discussion.

Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 40,582,357 625,207 24,695

           3,111,864

Proposal 4 - The vote, on a non-binding, advisory basis, on the frequency with which shareholders will be asked to cast a non-binding advisory vote on the compensation of the Company's named executive officers.





 One Year    Two Years   Three Years   Votes Abstained
40,859,648    66,251       266,131         40,229

Based on the foregoing votes, (a) Felix J. Baker, Tracey L. McCain and Kimberly J. Popovits were elected as Class III directors, (b) Proposal 2 was approved, (c) Proposal 3 was approved, and (d) the Company's shareholders recommended that future shareholder advisory votes on the compensation of the Company's named executive officers be held every year. In accordance with the results of the non-binding, advisory vote of the Company's shareholders and the recommendation of its board of directors, the Company has determined that future advisory votes on named executive compensation will be held every year until the next required advisory vote on the frequency of shareholder votes on executive compensation.

© Edgar Online, source Glimpses